Celcuity
CELCNASDAQHigh RiskCELsignia: a functional signaling pathway analysis platform that identifies abnormal signaling in patient tumor cells to guide targeted therapy selection and enable more precise clinical trials.
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
Market cap
Micro cap
Cash position
$100M as of Q2 2025
~25 months runway (derived)
Revenue status
pre revenue
Pipeline assets
7 programs
What does Celcuity do?
Celcuity is a small biotech company that's trying to develop a new cancer drug called gedatolisib. This drug works by blocking a specific pathway inside cancer cells that helps them grow. They are testing it mainly in breast cancer, especially a type called HR-positive, HER2-negative, which is the most common kind. The idea is to give gedatolisib together with other treatments to make them work better. They also have a special test called CELsignia that looks at the actual signaling in a patient's tumor to see if they might respond to certain drugs. This could help match the right drug to the right patient. For investors, the big thing to watch is the results of a large phase 3 trial called VIKTORIA-1, which is testing gedatolisib in advanced breast cancer. If the results are good, the company could get approval and start selling the drug, which would be a huge deal for a company this size. But there are risks: the drug might not work well enough, or it might have side effects that are hard to manage. Also, the company is spending money faster than it's making it, so they might need to raise more cash in the future. Overall, it's a high-risk, high-reward situation.
What to watch
Monitor VIKTORIA-1 data release (expected Q4 2025) for progression-free survival and safety.
Track any updates on the CELsignia diagnostic test adoption and reimbursement.
Watch for financing announcements or cash runway updates in quarterly reports.
Follow presentations at major oncology conferences (ASCO, ESMO) for interim data.
Keep an eye on competitive developments in HR+/HER2- breast cancer, such as new CDK4/6 inhibitors or oral SERDs.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Gedatolisib | HR+/HER2- advanced breast cancer | Phase 3 | Q4 2025 | ▼ |
| Gedatolisib | HR+/HER2- advanced breast cancer (first-line) | Phase 3 | 2027 | ▼ |
| Gedatolisib | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 1 | 2026 | ▼ |
| Gedatolisib | Endometrial cancer | Phase 2 | 2025 | ▼ |
| Gedatolisib | Advanced triple-negative or BRCA1/2 positive, HER2-negative breast cancer | Phase 1 | 2025 | ▼ |
| Neratinib + Capmatinib | Metastatic breast cancer with abnormal HER-family and c-Met activity | Phase 1 | Terminated | ▼ |
| Neratinib | Triple-negative breast cancer with abnormal HER2 signaling | Phase 2 | Unknown | ▼ |
Investment thesis
Bull case
Celcuity's lead candidate gedatolisib has shown promising efficacy in HR+/HER2- breast cancer, a large market. The VIKTORIA-1 trial is fully enrolled and data is expected in late 2025. If positive, gedatolisib could become a new standard of care in combination with fulvestrant, potentially replacing or complementing CDK4/6 inhibitors. The company's CELsignia diagnostic platform could enable precision medicine, increasing response rates and differentiating it from competitors. With a cash runway into 2027, Celcuity is well-funded to reach key milestones. The stock is currently micro-cap, offering significant upside if the drug succeeds.
Bear case
Gedatolisib is a pan-PI3K/mTOR inhibitor, a class that has historically faced toxicity and modest efficacy. The VIKTORIA-1 trial may not show a significant improvement over existing therapies, especially given the emergence of oral SERDs and novel CDK4/6 inhibitors. The company is heavily dependent on a single drug; any clinical hold or safety issue could be devastating. Additionally, the CELsignia test is unproven commercially and may not gain adoption. With no revenue and high burn rate, dilution risk is high if data disappoints. Competition from large pharma with deep pockets is intense.
Key upcoming catalysts
VIKTORIA-1 data readout
Q4 2025
Unverified — this date has not been checked against a primary source.
Interim data from VIKTORIA-2
2026
Unverified — this date has not been checked against a primary source.
Presentation at ASCO 2025
June 2025
Unverified — this date has not been checked against a primary source.
Regulatory meeting with FDA
2025
Unverified — this date has not been checked against a primary source.
Risk factors
Clinical trial failure: Gedatolisib may not meet primary endpoints in VIKTORIA-1 or VIKTORIA-2.
Safety concerns: PI3K/mTOR inhibitors are associated with hyperglycemia, rash, and other toxicities that could limit adoption.
Dependence on single drug: Pipeline is heavily concentrated on gedatolisib; other programs are early stage or terminated.
Diagnostic platform risk: CELsignia may not be widely adopted or may not improve outcomes as expected.
Competition: Large pharma with established drugs and greater resources may outcompete in the same indications.
Financing risk: As a pre-revenue company, Celcuity may need to raise capital, leading to dilution.
Comparable companies
Financial snapshot
These figures are drafted by our AI pipeline, not read from SEC filings. Confirm anything you would act on against the company's latest 10-Q or 10-K.
Cash
$100M as of Q2 2025
Q2 2025 — 5 quarters ago
Quarterly burn
$12M
Cash runway
~25 months
$100M ÷ $12M per quarter
Revenue
pre revenue
Institutional ownership
70%
Source: company profile text. These figures come from the company profile text, not from a filing we have parsed. Check them against the latest 10-Q before relying on them.
These figures are out of date
The cash position cited here is from Q2 2025, roughly 5 quarters ago. The company has almost certainly reported since. Check its latest filing before using any of this.
Sponsored
Get premium CELC analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you